Literature DB >> 18606155

CD40 ligation mediates plaque-associated tau phosphorylation in beta-amyloid overproducing mice.

Vincent Laporte1, Ghania Ait-Ghezala, Claude-Henry Volmar, Christopher Ganey, Nowell Ganey, Marcie Wood, Michael Mullan.   

Abstract

Neuritic dystrophy with amyloid burden and neurofibrillary tangles are pathological hallmarks of Alzheimer's disease. Genetic disruption of CD40 or CD40L alleviates amyloid burden, astrocytosis, and microgliosis in transgenic animal models of Alzheimer's disease. It has been reported that phosphorylated tau-positive dystrophic neurites are observed in transgenic mice over-expressing human mutant beta-amyloid precursor protein (Tg2576). Here, we studied the pattern of phosphorylated tau (labeled with AT8, CP13, PG5, and PHF1 antibodies) and plaques using immunohistochemical techniques. Phosphorylated tau-positive dystrophic neurites were exclusively associated with Congo red-positive plaques as previously reported. Further, we show that CD40L or CD40 deficiency reduces the mean ratio of dystrophic neurite area to congophilic plaque area and the level of expression of cdk5 and p35/p25 in mice. In addition, we show that in a human neuroblastoma cell line treated with CD40L, cdk5 and p35/p25 are increased. Together, our data suggest that CD40-CD40L interaction has an effect on tau phosphorylation independent of beta-amyloid pathology, and that this effect may occur through a decrease of cdk5 and p35/p25.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18606155     DOI: 10.1016/j.brainres.2008.06.032

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  2 in total

1.  Genome-wide association study of working memory brain activation.

Authors:  Gabriëlla A M Blokland; Angus K Wallace; Narelle K Hansell; Paul M Thompson; Ian B Hickie; Grant W Montgomery; Nicholas G Martin; Katie L McMahon; Greig I de Zubicaray; Margaret J Wright
Journal:  Int J Psychophysiol       Date:  2016-09-23       Impact factor: 2.997

2.  M344 promotes nonamyloidogenic amyloid precursor protein processing while normalizing Alzheimer's disease genes and improving memory.

Authors:  Claude-Henry Volmar; Hasib Salah-Uddin; Karolina J Janczura; Paul Halley; Guerline Lambert; Andrew Wodrich; Sivan Manoah; Nidhi H Patel; Gregory C Sartor; Neil Mehta; Nancy T H Miles; Sachi Desse; David Dorcius; Michael D Cameron; Shaun P Brothers; Claes Wahlestedt
Journal:  Proc Natl Acad Sci U S A       Date:  2017-10-09       Impact factor: 11.205

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.